Literature DB >> 16401827

Thiopurine methyltransferase in acute lymphoblastic leukemia.

Mary V Relling, Ching-Hon Pui, Cheng Cheng, William E Evans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16401827     DOI： 10.1182/blood-2005-08-3379

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  49 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

3.  NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.

Authors:  Takaya Moriyama; Rina Nishii; Virginia Perez-Andreu; Wenjian Yang; Federico Antillon Klussmann; Xujie Zhao; Ting-Nien Lin; Keito Hoshitsuki; Jacob Nersting; Kentaro Kihira; Ute Hofmann; Yoshihiro Komada; Motohiro Kato; Robert McCorkle; Lie Li; Katsuyoshi Koh; Cesar Rolando Najera; Shirley Kow-Yin Kham; Tomoya Isobe; Zhiwei Chen; Edwynn Kean-Hui Chiew; Deepa Bhojwani; Cynthia Jeffries; Yan Lu; Matthias Schwab; Hiroto Inaba; Ching-Hon Pui; Mary V Relling; Atsushi Manabe; Hiroki Hori; Kjeld Schmiegelow; Allen E J Yeoh; William E Evans; Jun J Yang
Journal:  Nat Genet       Date:  2016-02-15       Impact factor: 38.330

Review 4.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

Review 5.  Creating and evaluating genetic tests predictive of drug response.

Authors:  Scott T Weiss; Howard L McLeod; David A Flockhart; M Eileen Dolan; Neal L Benowitz; Julie A Johnson; Mark J Ratain; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2008-06-20       Impact factor: 84.694

6.  Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Authors:  C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2016-11-18       Impact factor: 6.875

Review 7.  The pharmacogenomics of drug resistance to protein kinase inhibitors.

Authors:  Nancy K Gillis; Howard L McLeod
Journal:  Drug Resist Updat       Date:  2016-07-05       Impact factor: 18.500

8.  Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  K Schmiegelow; E Forestier; J Kristinsson; S Söderhäll; K Vettenranta; R Weinshilboum; F Wesenberg
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

Review 9.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

10.  Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Authors:  C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.